Cargando…

Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion+ tumors. Both drugs have phase I data, demonstrating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanman, Tyler, Hayden Gephart, Melanie, Bui, Nam, Toland, Angus, Nagpal, Seema
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787578/ https://www.ncbi.nlm.nih.gov/pubmed/35111018 http://dx.doi.org/10.1159/000521158

Ejemplares similares

Diagnostic and Therapeutic Updates in Leptomeningeal Disease
por: Roy-O’Reilly, Meaghan A., et al.
Publicado: (2023)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases
por: Li, Yingmei, et al.
Publicado: (2021)

TMP3-NTRK1 rearranged uterine sarcoma: A case report
por: Boyle, William, et al.
Publicado: (2020)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2022)

Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors
por: Khuong-Quang, Dong-Anh, et al.
Publicado: (2020)

NTRK1 Fusion in Glioblastoma Multiforme
por: Kim, Jinkuk, et al.
Publicado: (2014)

NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities
por: Nozzoli, Filippo, et al.
Publicado: (2022)

EML4–NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review
por: Dang, Xiaohe, et al.
Publicado: (2022)

Identifying patients with NTRK fusion cancer
por: Solomon, J P, et al.
Publicado: (2019)

NTRK fusion in Japanese colorectal adenocarcinomas
por: Yamashiro, Yuya, et al.
Publicado: (2021)

A review of NTRK fusions in cancer
por: Manea, Cristina Alexandra, et al.
Publicado: (2022)

A Single-Institution Retrospective Series of SARS-CoV-2 Infection in Adult Glioma Patients
por: Lanman, Tyler, et al.
Publicado: (2023)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
por: Torre, Matthew, et al.
Publicado: (2020)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
Publicado: (2014)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
por: Kang, Jeongwan, et al.
Publicado: (2020)

NTRK fusions in osteosarcoma are rare and non‐functional events
por: Ameline, Baptiste, et al.
Publicado: (2020)

NTRK Gene Fusion Detection in Atypical Spitz Tumors
por: Cappellesso, Rocco, et al.
Publicado: (2021)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
por: Konicek, Bruce W., et al.
Publicado: (2018)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma
por: Yu, Qing-Xiang, et al.
Publicado: (2023)

NTRK3 Overexpression in Undifferentiated Sarcomas with YWHAE and BCOR Genetic Alterations
por: Kao, Yu-Chien, et al.
Publicado: (2020)

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome
por: Zhao, Xiaonan, et al.
Publicado: (2021)

LPTO-06. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS
por: Deng, Jiaojiao, et al.
Publicado: (2019)

How I treat NTRK gene fusion-positive cancers
por: Lassen, Ulrik
Publicado: (2019)

Dermoscopic Features of Spitz Tumor With LMNA-NTRK1 Fusion
por: Friedman, Ben J., et al.
Publicado: (2020)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
por: Zhao, Ruiying, et al.
Publicado: (2021)

Real-World Experience of NTRK Fusion–Positive Thyroid Cancer
por: Park, Jong Chul, et al.
Publicado: (2022)

NTRK Fusions in 1113 Solid Tumors in a Single Institution
por: Bang, Heejin, et al.
Publicado: (2022)

Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients
por: Silvertown, Joshua D., et al.
Publicado: (2022)

NTRK3 gene fusion in an adult ganglioglioma: illustrative case
por: Rubino, Sebastian, et al.
Publicado: (2022)

NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
por: Koehler, Viktoria Florentine, et al.
Publicado: (2023)

Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes
por: de la Fouchardière, Arnaud, et al.
Publicado: (2020)

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
por: Sigal, Darren S., et al.
Publicado: (2018)

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer
por: Park, Do Youn, et al.
Publicado: (2015)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis
por: Pekova, Barbora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8sbqcqum2umtjjm9ia0mde67v6